On Nortran's Website, the following is Bob Rieder's January Update:
The market that Viagra created but did not satisfy.
Sex always sells, but there have been few media obsessions that have equaled the Viagra story of early 1998. Both within the industry and in the non-medical press, the impending launch of Viagra, Pfizer's drug for treating erectile dysfunction, received little attention. But once the product was launched, and the testimonials began, everything
changed. Viagra became the darling of the media and a hugely selling drug - and the rest is history. Or is it?
What many people do not know is that reported sales of Viagra have been falling sharply in recent months, for some very good reasons: Viagra has been implicated in more than 100 deaths and may be effective in only a minority of real sexual dysfunction cases. Viagra's main legacy may be that it showed the pharmaceutical world that a huge market exists in the sexual dysfunction area, but ultimately did not satisfy that market.
That leaves a tremendous opportunity for Nortran.
Nortran's pro-erectile compound, RSD992, represents a completely novel approach to treating sexual dysfunction. It works on the central nervous system, so is ideal for treating the largest single segment of the sexual dysfunction market: that which is psychogenic in origin. Rather than compete with Viagra, Nortran's drug may make an
ideal complement to expand Viagra's usefulness.
Many large pharmaceutical companies have expressed interest in Nortran's project and - though it always takes longer than it should - we're confident that we will partner the project early in 1999.
|
